Fennec Pharmaceuticals Inc.
FENC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 4.06 | 0.50 | -0.24 | 0.55 |
| FCF Yield | 15.64% | -5.75% | -7.16% | -12.43% |
| EV / EBITDA | 45.89 | -25.55 | -11.22 | -799.30 |
| Quality | ||||
| ROIC | 41.07% | -66.06% | -101.16% | -83.49% |
| Gross Margin | 93.30% | 94.08% | 94.40% | 0.00% |
| Cash Conversion Ratio | -61.88 | 1.07 | 0.76 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | 218.30% | – | 105.45% | – |
| Free Cash Flow Growth | 257.38% | 5.07% | -26.97% | 8.80% |
| Safety | ||||
| Net Debt / EBITDA | -2.03 | -1.43 | -0.05 | 130.99 |
| Interest Coverage | 0.63 | -3.76 | -23.10 | -136.69 |
| Efficiency | ||||
| Inventory Turnover | 3.00 | 0.58 | 0.15 | 0.00 |
| Cash Conversion Cycle | -109.14 | -318.86 | -7,331.58 | 0.00 |